Edition:
India

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

3.95USD
16 Aug 2019
Change (% chg)

$0.05 (+1.28%)
Prev Close
$3.90
Open
$3.90
Day's High
$4.07
Day's Low
$3.90
Volume
167,709
Avg. Vol
203,626
52-wk High
$6.96
52-wk Low
$2.08

Latest Key Developments (Source: Significant Developments)

ADMA Biologics Q2 Loss Per Share $0.25
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS SECOND QUARTER AND FIRST HALF 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.Q2 REVENUE ROSE 41 PERCENT TO $6.6 MILLION.Q2 REVENUE ESTIMATE $3.3 MILLION -- REFINITIV IBES DATA.COMMERCIAL LAUNCHES AND SALES OF BIVIGAM® AND ASCENIV™ IN SECOND HALF OF 2019.WE EXPECT TO GENERATE ADDITIONAL REVENUE UNDER BPC CONTRACT DURING SECOND HALF OF 2019.  Full Article

Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb
Monday, 8 Jul 2019 

July 8 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS RECEIVES FDA APPROVAL FOR LICENSE TRANSFERS FOR BIVIGAM AND NABI-HB.ADMA BIOLOGICS - FDA NOTIFIED LICENSES FOR BIVIGAM & NABI-HB REVOKED FROM BIOTEST PHARMACEUTICALS & TRANSFERRED, ISSUED TO CO'S U.S. LICENSE NO. 2019.  Full Article

Adma Biologics Prices Public Offering Of Common Stock At $4.00 Per Share
Friday, 17 May 2019 

May 17 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.3 MILLION COMMON SHARES PRICED AT $4.00PER SHARE.  Full Article

Adma Biologics Announces Proposed $45 Million Public Offering Of Common Stock
Thursday, 16 May 2019 

May 15 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ANNOUNCES PROPOSED $45 MILLION PUBLIC OFFERING OF COMMON STOCK.ADMA BIOLOGICS - TO USE NET PROCEEDS TO SUPPORT COMMERCIAL LAUNCH OF ASCENIV ANTICIPATED DURING H2, FOR COMMERCIAL RELAUNCH OF BIVIGAM, AMONG OTHERS.  Full Article

ADMA Biologics Reports Q1 Loss Per Share $0.28
Thursday, 9 May 2019 

May 8 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.28.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.Q1 REVENUE $3.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.2 MILLION.  Full Article

Adma Biologics Elects To Draw-Down $27.5 Mln In Capital From Existing Perceptive Advisors Credit Agreement
Friday, 3 May 2019 

May 3 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ELECTS TO DRAW-DOWN $27.5 MILLION IN CAPITAL FROM EXISTING PERCEPTIVE ADVISORS CREDIT AGREEMENT.ADMA BIOLOGICS INC - ELECTED TO DRAW-DOWN $27.5 MILLION FROM ITS EXISTING CREDIT AGREEMENT WITH PERCEPTIVE ADVISORS.ADMA BIOLOGICS - CO, PERCEPTIVE ADVISORS ENTERED AMENDMENT, PROVIDING FOR AN UPSIZED, FUNDING TRANCHE COMMITMENT UPON GETTING FDA APPROVAL OF BIVGAM.ADMA BIOLOGICS INC - ADDITIONAL $12.5 MILLION COMMITMENT WILL BE AVAILABLE TO ADMA AT ITS SOLE OPTION FOLLOWING FDA APPROVAL UNTIL MARCH 31, 2020.  Full Article

FDA Approves ADMA Biologic's Immunodeficiency Disease Treatment Asceniv
Tuesday, 2 Apr 2019 

April 1 (Reuters) - ADMA Biologics Inc ::FDA APPROVES ASCENIV, A NOVEL INTRAVENOUS IMMUNE GLOBULIN.COMPANY ANTICIPATES HAVING PRODUCT AVAILABLE FOR COMMERCIAL LAUNCH DURING SECOND HALF OF 2019.ADMA BIOLOGICS - ASCENIV APPROVED FOR USE IN TREATMENT OF PRIMARY HUMORAL IMMUNODEFICIENCY DISEASE IN ADULTS, ADOLESCENTS (12 TO 17 YEARS OF AGE).FDA APPROVAL TRIGGERS FUNDING UP TO $27.5 MILLION FROM EXISTING CREDIT FACILITY WITH PERCEPTIVE ADVISORS.ASCENIV PIVOTAL PHASE III CLINICAL STUDY FOLLOWED FDA GUIDANCE FOR TREATMENT OF PATIENTS WITH PI.  Full Article

ADMA Biologics Enters Into $72.5 Mln Loan Facility With Perceptive Advisors
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ENTERS INTO $72.5 MILLION LOAN FACILITY WITH PERCEPTIVE ADVISORS.ADMA BIOLOGICS INC - PERCEPTIVE CREDIT AGREEMENT HAS AN INTEREST ONLY TERM WITH A MATURITY DATE OF MARCH 1, 2022.ADMA BIOLOGICS INC - NEW PERCEPTIVE LOAN FACILITY DOES NOT INCLUDE ANY BACK-END FEES.  Full Article

Adma Biologics Provides Regulatory Update For Bivigam
Thursday, 11 Oct 2018 

Oct 11 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS PROVIDES REGULATORY UPDATE FOR BIVIGAM®.ADMA BIOLOGICS INC - FDA HAS ESTABLISHED A TARGET ACTION DATE OF DECEMBER 18, 2018 FOR PAS UNDER PRESCRIPTION DRUG USER FEE ACT.ADMA BIOLOGICS - FDA CONSIDERS CO'S RECENT RESPONSE TO AGENCY'S INFORMATION REQUEST RELATED TO PRIOR APPROVAL SUPPLEMENT SUBMISSION A MAJOR AMENDMENT.ADMA BIOLOGICS - FDA COMMUNICATION RECEIVED BY CO HAS NO IMPACT ON OTHER ONGOING AGENCY INTERACTIONS OR TO RECENT RI-002 BLA RESUBMISSION.ADMA BIOLOGICS - FDA HAS INFORMED CO THAT THEY REQUIRE MORE 2 MONTHS TO COMPLETE THEIR REVIEW OF PAS SUBMITTED IN JUNE 2018 TO AMEND BLA FOR BIVIGAM.  Full Article

ADMA Biologics Reports FDA Compliance Status For Manufacturing Facility
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FDA COMPLIANCE STATUS FOR ITS MANUFACTURING FACILITY HAS IMPROVED.ADMA BIOLOGICS INC - RI-002'S BIOLOGICS LICENSE APPLICATION RESUBMISSION TARGETED FOR Q3 2018.ADMA BIOLOGICS INC - FDA INSPECTION DATABASE CONFIRMS VAI STATUS OF BOCA RATON, FL FACILITY.ADMA BIOLOGICS INC - WILL ANNOUNCE RELATED INFORMATION PERTAINING TO RI-002'S BLA FILING WHEN COMPANY RECEIVES CORRESPONDENCE FROM FDA.  Full Article